Basic & Clinical Medicine ›› 2023, Vol. 43 ›› Issue (9): 1462-1466.doi: 10.16352/j.issn.1001-6325.2023.09.1462
• Mini Reviews • Previous Articles Next Articles
DAI Di, LIU Yuqin*
Received:
2022-09-23
Revised:
2023-02-20
Online:
2023-09-05
Published:
2023-09-01
Contact:
*liuyuqin@pumc.edu.cn
CLC Number:
DAI Di, LIU Yuqin. Diagnostic difficulties and treatment progress of primary gastric lymphoma[J]. Basic & Clinical Medicine, 2023, 43(9): 1462-1466.
[1] | 吕远, 王晓娜, 梁寒. 原发性胃淋巴瘤200例临床分析[J]. 中华胃肠外科杂志, 2012, 15: 157-160. |
[2] | Carboni F, Diodoro MG, Valle M. Synchronous primary diffuse large B cell lymphoma and adenocarcinoma of the stomach: a clinical dilemma[J]. Indian J Surg Oncol, 2020, 11: 223-225. |
[3] | Meguro M, Someya T, Ohmura T, et al. Collision cancer of primary squamous cell carcinoma and adenocarcinoma in the stomach after treatment for a non-Hodgkin′s lymphoma of diffuse large B cell type:a case report[J]. Nihon Shokakibyo Gakkai Zasshi, 2020, 117: 334-344. |
[4] | Fukunaga H, Asama H, Kaneda H, et al. Collision tumor with diffuse large B cell lymphoma and gastric cancer[J]. Jpn J Clin Oncol, 2016, 46: 968-969. |
[5] | Kilaru S, Panda SS, Das H, et al. Primary gastric Hodgkin′s lymphoma: a rare coincidence[J]. Cancer Treat Res Commun, 2020, 24: 100194.doi:10.1016/j.ctarc.2020.100194. |
[6] | Zhang L, Zhang P, Wen J, et al. Primary gastric natural killer/T-cell lymphoma with diffuse CD30 expression and without CD56 expression: a case report[J]. Oncol Lett, 2016, 11: 969-972. |
[7] | Saber MM. Diagnostic performance of PD-L1 versus PD-1 expression in circulating CD20 cells in diffuse Large B-cell lymphoma[J]. Antibodies (Basel), 2022, 11.doi: 10.3390/antib11010015. |
[8] | Chen Y, Li M, Cao J, et al. CTLA-4 promotes lymphoma progression through tumor stem cell enrichment and immunosuppression[J]. Open Life Sci, 2021, 16: 909-919. |
[9] | American association for cancer research.LAG3-PD-1 Combo impresses in melanoma[J]. Cancer Discov, 2021, 11: 1605-1606. |
[10] | Jiang X, Zhang H, Ni J, et al. Identifying tumor antigens and immune subtypes of gastrointestinal MALT lymphoma for immunotherapy development[J]. Front Oncol, 2022, 12: 1060496.doi: 10.3389/fonc.2022.1060496. |
[11] | Nagasaki J, Togashi Y, Sugawara T, et al. The critical role of CD4+ T cells in PD-1 blockade against MHC-Ⅱ-expressing tumors such as classic Hodgkin lymphoma[J]. Blood Adv, 2020, 4: 4069-4082. |
[12] | Ma J, Pang X, Li J, et al. The immune checkpoint expression in the tumor immune microenvironment of DLBCL: clinicopathologic features and prognosis[J]. Front Oncol, 2022, 12: 1069378.doi: 10.3389/fonc.2022.1069378. |
[13] | Morrissey MA, Williamson AP, Steinbach AM, et al. Chimeric antigen receptors that trigger phagocytosis[J]. Elife, 2018, 7.doi: 10.7554/eLife.36688. |
[14] | Dovedi SJ, Elder MJ, Yang C, et al. Design and efficacy of a monovalent bispecific PD-1/CTLA4 antibody that enhances CTLA4 blockade on PD-1(+) activated T cells[J]. Cancer Discov, 2021, 11: 1100-1117. |
[15] | Palmeri M, Mehnert J, Silk AW, et al. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers[J]. ESMO Open, 2022, 7: 100336. doi: 10.1016/j.esmoop.2021.100336. |
[16] | Shi Y, Su H, Song Y, et al. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab[J]. EBioMedicine, 2020, 54: 102731.doi: 10.1016/j.ebiom.2020.102731. |
[17] | Schalper KA, Carleton M, Zhou M, et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors[J]. Nat Med, 2020, 26: 688-692. |
[18] | Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study[J]. Lancet, 2020, 396: 839-852. |
[19] | Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma[J]. N Engl J Med, 2019, 380: 45-56. |
[20] | Hamadani M, Radford J, Carlo-Stella C, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma[J]. Blood, 2021, 137: 2634-2645. |
[21] | Albinger N, Pfeifer R, Nitsche M, et al. Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia[J]. Blood Cancer J, 2022, 12: 61.doi: 10.1038/s41408-022-00660-2. |
[22] | Soldierer M, Bister A, Haist C, et al. Genetic engineering and enrichment of human NK cells for CAR-enhanced immunotherapy of hematological malignancies[J]. Front Immunol, 2022, 13: 847008. doi: 10.3389/fimmu.2022.847008. |
[23] | Mukhopadhyay M. Macrophages enter CAR immunotherapy[J]. Nat Methods, 2020, 17: 561.doi: 10.1038/s41592-020-0862-4. |
[24] | Klichinsky M, Ruella M, Shestova O, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy[J]. Nat Biotechnol, 2020, 38: 947-953. |
[25] | Zhang W, Liu L, Su H, et al. Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix[J]. Br J Cancer, 2019, 121: 837-845. |
[26] | Kang M, Lee SH, Kwon M, et al. Nanocomplex-mediated in vivo programming to chimeric antigen receptor-M1 macrophages for cancer therapy[J]. Adv Mater, 2021, 33: e2103258.doi: 10.1002/adma.202103258. |
[1] | . Drug therapy for intracranial germ cell tumor [J]. Basic & Clinical Medicine, 2024, 44(10): 1350-1356. |
[2] | . Advances in pharmacotherapy for angiosarcoma [J]. Basic & Clinical Medicine, 2024, 44(10): 1363-1367. |
[3] | . Targeted therapy and immunotherapy for malignant mesothelioma [J]. Basic & Clinical Medicine, 2024, 44(10): 1342-1349. |
[4] | YAN Chenhong, JIN Er. Progress of exosomal PD-L1 in diagnosis and treatment of non-small cell lung cancer [J]. Basic & Clinical Medicine, 2023, 43(9): 1457-1461. |
[5] | WU Qi, WANG Shaobo. Progress in CRISPR/Cas9 for CAR-T cell therapy of tumors [J]. Basic & Clinical Medicine, 2023, 43(8): 1313-1316. |
[6] | CHEN Zhongjie, HUANG Jiaru, HU Qing, ZHAO Zhenqin, CHEN Qiaoqiao, SUN Junyuan, JIA Jing. Progress on the pathological roles of immune checkpoint CD276 protein in tumorigenesis and development [J]. Basic & Clinical Medicine, 2023, 43(7): 1143-1147. |
[7] | LI Zhen, DUAN Zhaojun, LUO Yunping. Ganglioside GD2 is a potential candidate marker for lung cancer stem cells [J]. Basic & Clinical Medicine, 2023, 43(5): 777-784. |
[8] | GAN Zi-ying, TANG Hui. Research progress of oncolytic virus combined with PD-1/PD-L1 inhibitors [J]. Basic & Clinical Medicine, 2022, 42(4): 651-655. |
[9] | SI Xiao-yan, WANG Han-ping, ZHANG Li, WANG Meng-zhao, ZHANG Xiao-tong. Cytokine release syndrome caused by immune checkpoint inhibitor: a case report [J]. Basic & Clinical Medicine, 2022, 42(11): 1764-1766. |
[10] | GUO Xiao-peng, XING Bing, MA Wen-bin. Immune microenvironment and immunotherapy of pituitary adenomas [J]. Basic & Clinical Medicine, 2022, 42(1): 173-178. |
[11] | ZHANG Ruo-xi, HAN Bing. Progress of immune checkpoint inhibitors for the treatment of myelodysplastic syndrome [J]. Basic & Clinical Medicine, 2021, 41(8): 1210-1215. |
[12] | LI Qian, LIU Chun-hua, WANG Chen-yi, TAN Jiao-jiao, MA Yu-ping, LYU Hai-hong. Progress of study on inflammatory factors regulating function of vascular endothelial cells from type 1 diabetes mellitus [J]. Basic & Clinical Medicine, 2021, 41(10): 1497-1501. |
[13] | LI Jia-yi, XING Bing. Research progress of immune checkpoint inhibitor related autoimmune hypophysitis [J]. Basic & Clinical Medicine, 2020, 40(3): 403-406. |
[14] | . Exploration of possible different molecules between EBV associated and non-associated gastric cancer by omics [J]. Basic & Clinical Medicine, 2018, 38(7): 933-937. |
[15] | Chen-Xi TONG Yin-Hong SONG. Progress of chimeric antigen receptor-modified T cell therapy for osteosarcoma [J]. Basic & Clinical Medicine, 2018, 38(7): 1012-1015. |
Viewed | ||||||||||||||||||||||||||||||||||||||||||||||||||
Full text 241
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Abstract 267
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||